Concord Healthcare Group (2453) H2 2024 earnings summary

Executive summary

• FY2024 revenue fell 27.9% YoY to RMB388.3m; net loss widened 13.7% to RMB484.8m, while adjusted net loss excluding listing expenses rose 5.5% to RMB443.9m.

• Guangzhou’s proton therapy center began full-scale clinical operations on Dec. 16, creating a new premium-care offering; the near-term outlook depends partly on scaling patient volume and revenue.

Financial highlights

• Gross loss widened 3.3% to RMB67.2m; gross margin was negative 17.3%, versus negative 12.1% in 2023.

• Other income and net gains rose to RMB62.7m from RMB10.0m, primarily due to gains on disposal of subsidiaries; loss before tax was RMB485.8m.

• Basic and diluted loss per share was RMB0.62, versus RMB0.56; no dividend was paid or proposed for 2024.

Outlook and guidance

• Priorities include expanding proton therapy, improving clinical capabilities and patient experience, deepening regional and international partnerships, and developing medical-insurance and AI offerings.

• Management expects the proton center to support sales performance; forecasts through Dec. 31, 2025 assume adequate working capital, continued banking facilities, and no adverse unforeseen circumstances.

• Remaining IPO proceeds are expected to be fully used by Dec. 31, 2025, subject to evolving business needs and market conditions.